8-K: Tempest Therapeutics Reports Q3 2025 Results, Pursues Strategic Alternatives

Tempest Therapeutics announced its third quarter 2025 financial results, reporting a significant decrease in cash and continued net losses while actively exploring strategic alternatives.

Summary

• Cash and cash equivalents decreased to $7.5 million as of September 30, 2025, from $30.3 million on December 31, 2024.
• Net loss for the third quarter of 2025 was $3.5 million ($0.79 per share), an improvement compared to $10.6 million ($5.32 per share) for the same period in 2024.
• Year-to-date net loss for the nine months ended September 30, 2025, was $22.2 million ($5.71 per share), compared to $28.0 million ($15.48 per share) for the same period in 2024.
• Research and development (R&D) expenses significantly decreased to $0.6 million in Q3 2025 from $7.6 million in Q3 2024, primarily due to re-prioritizing efforts towards exploring strategic alternatives.
• General and administrative (G&A) expenses remained stable at $3.0 million for Q3 2025 compared to Q3 2024.
• The company is continuing its strategic alternatives process with the goal of maximizing value for stockholders.
• Anticipates the start of the TPST-1495 Phase 2 trial in collaboration with the NCI and the Cancer Prevention Clinical Trials Network.
• Remains confident in the potential of amezalpat to transform the treatment of first-line HCC.
• Raised $4.1 million in net proceeds from a June 2025 registered direct offering and $2.8 million from an at-the-market offering program.

Sentiment

Score: 3

Explanation: While net loss improved, this was largely driven by a significant reduction in R&D spending due to a strategic shift towards exploring alternatives, rather than operational efficiency or clinical success. The substantial decline in cash reserves and the explicit mention of 'strategic alternatives' and 'going concern' risk in forward-looking statements indicate significant financial challenges and uncertainty about the company's future as an independent entity.

Positives

• Net loss significantly decreased to $3.5 million in Q3 2025 from $10.6 million in Q3 2024, and year-to-date net loss improved to $22.2 million from $28.0 million.
• Research and development expenses saw a substantial decrease of $7.0 million in Q3 2025 compared to Q3 2024, primarily due to re-prioritization of efforts.
• Successfully raised $4.1 million in net proceeds from a registered direct offering in June 2025 and $2.8 million from an at-the-market offering program.
• Anticipates the start of the TPST-1495 Phase 2 trial in collaboration with the NCI and Cancer Prevention Clinical Trials Network.
• Maintains confidence in the potential of amezalpat for first-line HCC treatment.

Negatives

• Cash and cash equivalents declined significantly to $7.5 million as of September 30, 2025, from $30.3 million on December 31, 2024.
• The company continues to incur net losses, with $3.5 million in Q3 2025 and $22.2 million year-to-date.
• The decrease in R&D expenses is attributed to 're-prioritizing efforts towards exploring strategic alternatives,' indicating a potential slowdown or halt in core drug development activities due to financial pressures.
• Actively pursuing a 'strategic alternatives process' suggests uncertainty about the company's standalone future and may include options like a sale, merger, or winding down.
• Cash used in operating activities for the nine months ended September 30, 2025, was $23.2 million, indicating a high burn rate.

Risks

• Volatility and uncertainty in the capital markets for biotechnology companies.
• Ability to continue to operate as a going concern.
• Availability of suitable third parties with which to conduct contemplated strategic transactions.
• Uncertainty regarding whether a strategic transaction will be pursued, or if pursued, completed on attractive terms or at all.
• Unexpected safety or efficacy data observed during preclinical or clinical trials.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Changes in expected or existing competition.
• Changes in the regulatory environment.
• Unexpected litigation or other disputes.

Future Outlook

The company is continuing its strategic alternatives process to maximize stockholder value. It looks forward to the start of the TPST-1495 Phase 2 trial in collaboration with the NCI and Cancer Prevention Clinical Trials Network and remains confident in the potential of amezalpat to transform the treatment of first-line HCC.

Management Comments

• "We are continuing our strategic alternatives process with the goal of maximizing value for stockholders."
• "In addition, we look forward to the start of the TPST-1495 Phase 2 in collaboration with the NCI and the Cancer Prevention Clinical Trials Network and remain confident in the potential of amezalpat to transform the treatment of first-line HCC and bring meaningful benefit to patients and their families."

Industry Context

The biotechnology industry is highly capital-intensive, with companies often relying on external funding to advance clinical pipelines. Tempest's pursuit of "strategic alternatives" and significant reduction in R&D spending, while common for companies facing cash constraints, signals a challenging period. Collaborations with entities like the NCI are positive for validating drug candidates and sharing development costs, but the overall financial position suggests a need for significant capital or a transformative event to continue operations effectively in a competitive landscape. The focus on oncology, particularly HCC, places it in a high-value but crowded therapeutic area.

Stakeholder Impact

• Shareholders face significant uncertainty due to the ongoing strategic alternatives process, potential dilution from recent capital raises, and the risk of the company's ability to continue as a going concern. The stock price is likely to be volatile.
• Employees may face potential for further workforce reductions given the re-prioritization of efforts and mention of 'one-time separation costs for employees terminated' in the G&A explanation.
• Patients may experience potential impact on the development timeline and availability of TPST-1495 and amezalpat if strategic alternatives do not materialize favorably or if the company faces further financial constraints.
• Creditors face increased risk due to declining cash reserves and 'going concern' uncertainty.

Next Steps

• Continue the strategic alternatives process to maximize stockholder value.
• Start the TPST-1495 Phase 2 trial in collaboration with the NCI and Cancer Prevention Clinical Trials Network.

Key Dates

Recommendation

The company's cash position is critically low, and the significant reduction in R&D is a direct result of exploring 'strategic alternatives,' which often implies a search for a buyer or a significant restructuring due to financial distress. The explicit mention of 'ability to continue to operate as a going concern' in the risk factors is a severe warning. While net losses decreased, this was achieved by cutting core development, not by generating revenue or achieving clinical milestones. The future of the company as an an independent, value-generating entity is highly uncertain, making it a high-risk investment with significant downside potential.

Keywords

Biotechnology, Clinical-stage, Cancer therapeutics, Oncology, Financial results, Strategic alternatives, TPST-1495, Amezalpat, HCC, R&D, Cash burn, Nasdaq